Search

… in Q1 2022 Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal … to changing lives through the creation of transformative RNA therapies for genetic eye diseases today announced that …

… supports ProQR’s strategic focus on the Axiomer® RNA editing technology platform and continued advancement of … company dedicated to changing lives through transformative RNA therapies, and Laboratoires Théa, the leading independent … Sepofarsen Sepofarsen (QR-110) is an investigational RNA therapy designed to restore vision in Leber congenital …

… expected H1 2022 Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal … to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today …

… ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs In … to changing lives through the creation of transformative RNA therapies, today provided an update on its ophthalmology … s epofarsen Sepofarsen (QR-110) is an investigational RNA therapy designed to restore vision in Leber congenital …

… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … 1/2 clinical trial of QR-421a, an investigational RNA therapy. The Stellar trial is a randomized, single ascending …

… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … allowing us to advance this important investigational therapy for all patients with Usher syndrome and nsRP due to …

… at the upcoming Seventh Annual Retinal Cell and Gene Therapy Innovation Summit and the ARVO 2022 Annual Meeting … to focus on accelerating the development of Axiomer ® RNA base-editing technology platform across multiple … to changing lives through the creation of transformative RNA therapies, today provided an update on its sepofarsen …

… ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across multiple … to changing lives through the creation of transformative RNA therapies, today reported its financial and operating … s epofarsen Sepofarsen (QR-110) is an investigational RNA therapy designed to restore vision in Leber congenital …

… ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across multiple … to changing lives through the creation of transformative RNA therapies, today reported its financial and operating … were presented at the Seventh Annual Retinal Cell and Gene Therapy Innovation Summit, April 29, 2022, and the …

… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … trial and is a first-in-class investigational RNA therapy designed to address the underlying cause of Leber …